DIAH

DIAH 2026

19 – 21 May 2026 | Bruges, Belgium

VEROVACCiNES

verovaccines.com/Halle, Germany
17 profile visits

About

VEROVACCiNES has developed a next-generation agile vaccine platform that enables rapid development of vaccines tailored to pathogen dynamics and geographically different strains, delivering faster availability, broader protection, improved scalability, and reduced development risk compared with classic vaccines. The company internally develops high-value vaccines with strong differentiation and validated its platform through the positive opinion of EMA and subsequent EU-wide marketing authorization of the VeroBlue-3 bluetongue virus serotype 3 vaccine. With this milestone, VEROVACCiNES has matured into a fully integrated vaccine developer capable of rapidly generating, developing, and registering vaccines across the EU.

Social media

Areas of Activity

Biotech/Biopharma

Representatives

Ulrike Diesterbeck

VEROVACCiNES

Stefan Bennewitz

VEROVACCiNES